Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Prostate Clear all

Conditions: Prostate Tumors
Interventions: MR-Guided Laser Ablation; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 95 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer
Interventions: Civasheet 60 Gy, Civasheet 75 Gy, Adjuvant external beam radiation therapy; Radiation
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Radio-Frequency Ablation (RFA) ENCAGE™; Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cancer
Interventions: FACBC PET-CT Imaging; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Prostate Cancer, Endometrial Cancer
Interventions: Rucaparib, Nivolumab; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer, Renal Cancer, Brain Cancer, ALS
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
Interventions: AZD4635, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 17
States / cities: Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more

Conditions: Androgen Axis Suppression, Prostatectomy, Prostate Cancer
Interventions: Apalutamide, Androgen Deprivation Therapy; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: Gilbert, Arizona • Chicago, Illinois • Kansas City, Kansas + 3 more

Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions: Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Prostate Radiation, Docetaxel; Drug · Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Prostate Cancer
Interventions: eRapa (encapsulated rapamycin); Drug
Lead sponsor: Rapamycin Holdings, Inc. dba Emtora Biosciences; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Glioblastoma, Esophageal Cancer, Radiotherapy, Magnetic Resonance Imaging, MRI, Prostate Cancer, Vulvar Cancer, Pediatric Glioblastoma Multiforme, Sarcoma
Interventions: MRI IMAGING; Diagnostic Test
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Cancer, Lung Cancer (Diagnosis), Prostate Cancer
Interventions: referral for definitive diagnosis based on their cancer screening results, Engagement; Behavioral
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Prostate Cancer
Interventions: Conventional Fractionated Intensity Modulated Radiotherapy, Hypofractionated Intensity Modulated Radiotherapy; Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer, Post-Brachytherapy Bladder Outlet Obstruction
Interventions: Memokath 028SW Urethral Stent; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 50 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases, Prostate Cancer, Liver Metastases, Oligoprogressive Nodal Metastases, Metachronous Nodal Metastases, Synchronous Nodal Metastases, Mesothelioma, Spine Metastases, Brain Metastases, Borderline Resectable Pancreatic Carcinoma
Interventions: MR-guided Linac; Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Head and Neck Cancer, Prostate Cancer
Interventions: novel PET tracer FACBC; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Adenocarcinoma, Lower Urinary Tract Symptoms
Interventions: Bicalutamide implant; Combination Product
Lead sponsor: Alessa Therapeutics Inc.; Industry
Eligibility: 35 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Revlimid; Drug
Lead sponsor: Oncology Specialists, S.C.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Niles, Illinois • Park Ridge, Illinois

Conditions: Prostatic Neoplasms
Interventions: GM-CSF, Ketoconazole, Mitoxantrone; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hormone-Refractory Prostate Cancer
Interventions: Zoledronic acid, Estramustine, Docetaxel; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
Interventions: 68 Ga-PSMA-11 prepared using a PSMA-11 Sterile Cold Kit; Drug
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older · Male only
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Prostate Cancer
Interventions: TRAQinform Theranostics; Device
Lead sponsor: AIQ Solutions; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Search by objective public record fields.

MR-Guided Laser Ablation of Prostate Bed Recurrences

CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation

Pilot Study on Focal Prostate Radio-Frequency Ablation

Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Trial of eRapa in Prostate Cancer Patients

Serial MRI Scans During Radiation Therapy

Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study

Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots

Investigation of Protein Biomarkers of Prostate Cancer

A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation

Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma

Stereotactic Magnetic Resonance Guided Radiation Therapy

The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer

A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients

Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly)

Comprehensive Assessment of Cancer Theranostic Response